论文部分内容阅读
目的探讨联合化疗方案PDF即紫杉醇(PTX)+顺铂(DDP)+5-氟尿嘧啶(5-Fu)治疗晚期胃癌的临床疗效情况和安全性。方法入选2008年1月至2010年12月期间晚期胃癌患者80例,随机分为治疗组(40例)和对照组(40例)。对照组患者采用5-Fu治疗。治疗组患者采用PTX(135 mg/m2)静脉滴注3 h,第1天;DDP(25 mg/m2)静脉滴注,第1~3天;5-Fu(750 mg/m2)静脉滴注,第1~5天,28天为1个化疗周期。2个周期后分析两组患者的疗效和不良反应。结果治疗组患者中,完全缓解(CR)8例,部分缓解(PR)10例,稳定(SD)15例,进展(PD)7例,临床有效率为45.0%,临床受益率为82.5%,明显高于对照组。治疗组患者的不良反应主要是骨髓抑制和消化道反应,症状较轻,不良反应明显低于对照组。结论采用联合化疗方案治疗晚期胃癌可提高疗效,且不良反应较轻,值得临床上推广。
Objective To investigate the clinical efficacy and safety of combined chemotherapy (PDF), ie paclitaxel (PTX) plus cisplatin (DDP) and 5-fluorouracil (5-Fu) in the treatment of advanced gastric cancer. Methods 80 patients with advanced gastric cancer from January 2008 to December 2010 were randomly divided into treatment group (40 cases) and control group (40 cases). Control group patients treated with 5-Fu. Patients in the treatment group received PTX (135 mg / m2) intravenously for 3 h on day 1; intravenous drip of DDP (25 mg / m2) on day 1 to 3; and 5-Fu , 1 to 5 days, 28 days for a chemotherapy cycle. Two cycles after the analysis of the efficacy and adverse reactions in both groups. Results In the treatment group, there were 8 cases of complete remission (CR), 10 cases of partial remission (PR), 15 cases of stable (SD) and 7 cases of progression (PD). The clinical effective rate was 45.0% and the clinical benefit rate was 82.5% Obviously higher than the control group. Adverse reactions in the treatment group were mainly myelosuppression and digestive tract reactions, with mild symptoms and adverse reactions, which were significantly lower than those in the control group. Conclusion The combination of chemotherapy regimen in the treatment of advanced gastric cancer can improve the curative effect, and the adverse reaction is mild, which is worth to be popularized clinically.